ReviewFrontiers in immunology2026
NAT10: a potential factor to reverse tumor chemotherapy resistance and radioresistance (Review).
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Erratum issued
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
NAT10 (N-acetyltransferase 10) is a nucleolar acetyltransferase with catalytic acetylation function, which is currently the only known acetyltransferase that catalyzes the N4-acetylcytidine (ac4C) modification in RNA. As the "writer" protein for ac4C, NAT10 plays a critical role in various biological and pathological processes. In this article, we first introduce the structural and functional characteristics of NAT10, followed by a comprehensive synthesis of its multifaceted molecular mechanisms orchestrating tumor radiotherapy and chemotherapy resistance. Specifically, we emphasize its roles in hyperactivating DNA damage repair (DDR), driving metabolic reprogramming (including evasion of ferroptosis), and facilitating tumor immune evasion via PD-L1 regulation and T-cell suppression. Furthermore, we critically evaluate the translational implications of NAT10-targeted interventions, highlighting the therapeutic promise of specific inhibitors like Remodelin and the repurposed FDA-approved drug Fludarabine. We believe that understanding the functions and mechanisms of NAT10 in tumors will significantly improve the diagnosis, treatment, and prognosis of cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.